Skip to main content

Table 1 Characteristics of patients at ICU admission a

From: CD8+T-cell counts: an early predictor of risk and mortality in critically ill immunocompromised patients with invasive pulmonary aspergillosis

Variables

All patients (n = 150)

No IPA (n = 88, 58.7%)

IPA (n = 62, 41.3%)

No IPA vs IPA Pvalue

Mean age (yr)

45.9 ± 19.8

42.3 ± 20.4

50.9 ± 17.9

0.009

Gender (males:females)

59:91

31:57

28:34

0.239

Resource (Emergency:Ward)

82:68

50:38

32:30

0.618

Mean HLOS before ICU admission (days)

9.0 (23.0)

9.0 (18.0)

18.9 ± 21.4

0.738

Underlying disease,bn (%)

    

 COPD

27 (18.0)

17 (19.3)

10 (16.1)

0.615

 Diabetic mellitus

22 (14.7)

9 (10.2)

13 (21.0)

0.069

 Liver cirrhosis/hepatic failure

17 (11.3)

7 (8.0)

10 (16.1)

0.12

 Chronic renal failure

21 (14.0)

12 (13.6)

9 (14.5)

0.923

Immunocompromised host factors,cn (%)

    

Immune system disease, n (%)

112 (74.7)

65 (73.9)

47 (75.8)

0.85

 SLE

54 (36.0)

35 (39.8)

19 (30.6)

0.251

 MCTD

19 (12.7)

12 (13.6)

7 (11.3)

0.671

 MPA

15 (10.0)

5 (5.7)

10 (16.1)

0.035

 Others

24 (16.0)

13 (14.8)

11 (17.7)

0.625

Hematologic malignancy, n (%)

26 (17.3)

16 (18.2)

10 (16.1)

0.744

Solid tumor, n (%)

9 (6.0)

6 (6.8)

3 (4.8)

0.615

Transplantation,dn (%)

9 (6.0)

5 (5.7)

4 (6.5)

0.845

Steroid treatment,en (%)

48 (32.0)

27 (30.7)

21 (33.9)

0.724

Steroide and T-cell immunosuppressant, n (%)

53 (35.3)

27 (30.7)

26 (41.9)

0.169

Steroid dosagef (mg)

480.0 (1,250.0)

480.0 (1,000.0)

600.0 (720.0)

0.023

Chemotherapy, n (%)

27 (18.0)

20 (22.7)

7 (11.3)

0.086

Antifungal treatment,gn (%)

18 (12.0)

10 (11.4)

8 (12.9)

0.803

Biochemical parameters at ICU admission

    

 Creatinine level (μmol/L)

137.2 (97.3)

135.4 (100.0)

139.8 (94.5)

0.564

 Albumin level (g/L)

28.6 ± 5.0

29.1 ± 5.3

27.9 ± 4.5

0.173

 Blood glucose level (mg/dl)

171.1 ± 66.2

168.8 ± 68.6

174.5 ± 63.0

0.615

APACHE II score

18.3 ± 5.4

18.2 ± 5.4

18.4 ± 5.4

0.793

SOFA score

8.6 ± 3.9

8.3 ± 3.6

9.2 ± 4.2

0.165

  1. aAPACHE II Acute Physiology and Chronic Health Evaluation II, COPD chronic obstructive pulmonary disease, HLOS hospital length of stay, MCTD mixed connective tissue disease, MPA microscopic polyangitis, IPA invasive pulmonary aspergillosis, SLE systemic lupus erythematosus, SOFA Sequential Organ Failure Assessment. Continuous variables are expressed as the means ± SD or medians (IQR). All other data are raw numbers (%). bThis variable was defined as the predisposing conditions that have been described associated with the development of IPA in critically ill patients; organ failure was defined as a SOFA score of ≥3 for any system. cHost factors were defined according to the IFD classification in the 2008 EORTC-MSG criteria [6]. dVariable included solid-organ and hematopoietic stem cell transplantation. eAll steroid treatments indicated were defined according to the 2008 EORTC-MSG criteria: mean minimum dose of 0.3 mg/kg/day prednisone equivalent for more than 3 weeks before ICU admission. Other corticosteroids should be converted into equivalent dose of prednisone before calculation and comparison. fVariable defined as total amount of steroid treatment, alone and combined with other immunosuppressive agents. gVariable defined as treatment with systemic antifungal drugs including fluconazole, voriconazole, caspofungin and amphotericin B for 48 hours or more in the preceding week.
Back to article page

Critical Care

ISSN: 1364-8535